Grade ≥3 adverse events during induction treatment
| Grade ≥3 adverse event . | MPR (n = 211) No. (%) . | CPR (n = 220) No. (%) . | Rd (n = 212) No. (%) . |
|---|---|---|---|
| Hematologic | |||
| At least one event | 143 (68) | 71 (32) | 61 (29) |
| Anemia | 32 (15) | 14 (6) | 9 (4) |
| Neutropenia* | 136 (64) | 63 (29) | 52 (25) |
| Thrombocytopenia | 37 (18) | 19 (9) | 15 (7) |
| Nonhematologic | |||
| At least one event | 66 (31) | 66 (30) | 63 (30) |
| Cardiologic | 9 (4.5) | 11 (6) | 13 (6) |
| Arrythmia | 2 (1) | 2(1) | 3 (1.5) |
| Acute myocardial infarction | 1 (0.5) | 4(2) | 4 (2) |
| Heart failure | 2(1) | 3(1.5) | 4 (2) |
| Other | 4(2) | 2(1) | 2 (1) |
| Vascular | 7 (3.5) | 12 (5) | 7 (3) |
| Deep vein thrombosis/thromboembolism | 6 (3) | 10 (5) | 5 (2) |
| Stroke | 1 (0.5) | 2 (1) | 2 (1) |
| Constitutional | 19 (9.5) | 7 (3.5) | 11 (5) |
| Fever | 10 (5) | 2 (1) | 3 (1.5) |
| Fatigue | 6 (3) | 4(2) | 5(2) |
| Other | 3 (1.5) | 1(0.5) | 3(1.5) |
| Dermatologic | 9 (5) | 17 (8) | 11 (5) |
| Infection | 23 (11) | 16 (6.5) | 20 (9) |
| Pneumonia | 2 (1) | 6(2.5) | 4(2) |
| Bronchitis | 1 (0.5) | 0 | 3 (1.5) |
| Sepsis | 2 (1) | 2 (1) | 2 (1) |
| Enteritis | 0 | 2 (1) | 2 (1) |
| Febrile neutropenia | 8 (4) | 4 (2) | 3 (1.5) |
| Viral reactivation | 6 (2) | 0 | 1 (0.5) |
| Other/not specified | 4 (1) | 2 (1) | 5 (1) |
| Peripheral neurolopathy | 6 (3) | 6 (3) | 5 (2) |
| Second primary malignancies | 3 (1.5) | 2 (1) | 0 |
| Hematologic | 0 | 1 (0.5) | 0 |
| Solid | 3 (1.5) | 1 (0.5) | 0 |
| Discontinuation due to adverse events | 37 (18) | 33 (15) | 30 (14) |
| Grade ≥3 adverse event . | MPR (n = 211) No. (%) . | CPR (n = 220) No. (%) . | Rd (n = 212) No. (%) . |
|---|---|---|---|
| Hematologic | |||
| At least one event | 143 (68) | 71 (32) | 61 (29) |
| Anemia | 32 (15) | 14 (6) | 9 (4) |
| Neutropenia* | 136 (64) | 63 (29) | 52 (25) |
| Thrombocytopenia | 37 (18) | 19 (9) | 15 (7) |
| Nonhematologic | |||
| At least one event | 66 (31) | 66 (30) | 63 (30) |
| Cardiologic | 9 (4.5) | 11 (6) | 13 (6) |
| Arrythmia | 2 (1) | 2(1) | 3 (1.5) |
| Acute myocardial infarction | 1 (0.5) | 4(2) | 4 (2) |
| Heart failure | 2(1) | 3(1.5) | 4 (2) |
| Other | 4(2) | 2(1) | 2 (1) |
| Vascular | 7 (3.5) | 12 (5) | 7 (3) |
| Deep vein thrombosis/thromboembolism | 6 (3) | 10 (5) | 5 (2) |
| Stroke | 1 (0.5) | 2 (1) | 2 (1) |
| Constitutional | 19 (9.5) | 7 (3.5) | 11 (5) |
| Fever | 10 (5) | 2 (1) | 3 (1.5) |
| Fatigue | 6 (3) | 4(2) | 5(2) |
| Other | 3 (1.5) | 1(0.5) | 3(1.5) |
| Dermatologic | 9 (5) | 17 (8) | 11 (5) |
| Infection | 23 (11) | 16 (6.5) | 20 (9) |
| Pneumonia | 2 (1) | 6(2.5) | 4(2) |
| Bronchitis | 1 (0.5) | 0 | 3 (1.5) |
| Sepsis | 2 (1) | 2 (1) | 2 (1) |
| Enteritis | 0 | 2 (1) | 2 (1) |
| Febrile neutropenia | 8 (4) | 4 (2) | 3 (1.5) |
| Viral reactivation | 6 (2) | 0 | 1 (0.5) |
| Other/not specified | 4 (1) | 2 (1) | 5 (1) |
| Peripheral neurolopathy | 6 (3) | 6 (3) | 5 (2) |
| Second primary malignancies | 3 (1.5) | 2 (1) | 0 |
| Hematologic | 0 | 1 (0.5) | 0 |
| Solid | 3 (1.5) | 1 (0.5) | 0 |
| Discontinuation due to adverse events | 37 (18) | 33 (15) | 30 (14) |
Administration of granulocyte colony-stimulating factor: Rd, 43 (20%); MPR, 120 (57%); CPR, 51 (23%).